BPC-157 Research Guide

Tissue and recovery research peptide

BPC-157 is a stable synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Across more than two decades of preclinical research, it has shown broad cytoprotective and tissue-healing effects in models of tendon injury, gut inflammation, nerve damage, and ischemic injury — work that has made it one of the most-studied compounds in the modern peptide research literature.

15 amino acids Pentadecapeptide

Multi-tissue Cytoprotective

Stable pH and protease tolerant

What is BPC-157?

BPC-157 stands for Body Protective Compound, isolated as a fifteen-amino-acid fragment of a larger gastric protective protein originally identified in the 1990s by Sikiric and colleagues at the University of Zagreb. Its sequence is GEPPPGKPADDAGLV, and its key research property is unusual stability — it remains intact in human gastric juice and resists most enzymatic degradation pathways that limit other small peptides.

In the research literature, BPC-157 is studied for cytoprotective effects across an unusually broad set of tissue types. Published animal models cover tendon and ligament repair, gastric ulcer healing, gut barrier integrity, vascular angiogenesis, central nervous system regeneration after trauma, and ischemic injury recovery. The breadth of activity is part of what has made it a focal point for peptide research outside the major pharmaceutical pipelines.

Aeternum Labs supplies BPC-157 as a lyophilized 5 mg vial. Every batch is verified to 99%+ purity by HPLC with mass spectrometry confirmation of the sequence, LAL endotoxin screening, and a public Certificate of Analysis tied to the batch lot number.

Mechanism of action

The molecular targets of BPC-157 are not fully characterized, which is unusual for a peptide with this much published research behind it. Several mechanisms are proposed in the literature and supported by reproducible animal data.

Vascular endothelial growth factor (VEGF) pathway upregulation is consistently observed in BPC-157 studies of wound healing and tissue repair. The peptide appears to drive angiogenesis at injury sites, which supports faster perfusion of repair tissue. This is the most reproducible mechanism in the published literature.

Nitric oxide synthase modulation is implicated across cardiovascular and gastrointestinal protection studies. BPC-157 appears to interact with both endothelial NOS and inducible NOS pathways depending on the tissue and condition studied.

Growth hormone receptor expression upregulation has been observed in tendon fibroblast cultures, providing a mechanistic basis for the consistent tendon-repair findings in animal models. This is a particularly active research area given the practical implications for orthopedic research.

Research history

BPC-157 was first characterized in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, who isolated the parent BPC molecule from human gastric juice and identified the active fifteen-amino-acid fragment. The Sikiric group has published more than three hundred peer-reviewed papers on BPC-157 across the subsequent three decades, making them the dominant contributor to the literature.

The first wave of research focused on gastric and intestinal protection, where BPC-157 showed efficacy across NSAID-induced ulcers, alcohol-induced gastric injury, and inflammatory bowel models. The second wave expanded to musculoskeletal applications, with multiple independent groups reproducing the Achilles tendon and medial collateral ligament repair findings.

More recent research has explored CNS effects (traumatic brain injury models, spinal cord injury models, neuropathic pain models) and cardiovascular effects (myocardial infarction models, vascular injury models). The breadth of the published literature is unusual for any single research compound.

Half-life and pharmacokinetics

BPC-157 demonstrates unusual oral bioavailability for a peptide of its size. Animal studies have shown therapeutic effects from oral, intraperitoneal, intramuscular, and subcutaneous administration routes, suggesting the peptide either survives gastrointestinal digestion or generates active metabolites that retain biological activity.

Plasma half-life data are limited compared to commercial pharmaceutical peptides because BPC-157 has not been the subject of formal pharmacokinetic studies in humans. Animal data suggest a relatively short plasma half-life with extended tissue effects, consistent with a peptide that exerts its activity locally rather than systemically.

Typical research doses

Animal research dose ranges in the published literature span approximately 10 microgram/kg to 10 mg/kg, with most studies using doses in the 10–500 microgram/kg range. Human-equivalent calculations using standard species-conversion factors place corresponding investigational doses in the low-microgram to low-milligram range per administration.

Frequency of administration in animal studies ranges from once daily to twice weekly depending on the endpoint studied. Tissue-repair models typically use daily dosing for the duration of the healing window. Gastrointestinal protection studies often use twice-daily dosing during active injury models.

Reconstitution protocol

Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.

Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.

Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.

For BPC-157, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Each 0.1 mL contains 250 microgram, allowing fine titration across the typical research dose range without sub-milliliter measurement difficulty.

Storage and stability

Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.

Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.

Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.

Common stack pairings

BPC-157 + TB-500 (broad tissue and recovery research)

TB-500 (thymosin beta-4 fragment) acts via actin-sequestering and cell-migration mechanisms distinct from BPC-157’s VEGF and NOS pathways. The combination is the most-studied dual peptide stack in tissue-repair research, with published reports across muscle, tendon, and CNS injury models.

BPC-157 + KPV (gut-focused research)

KPV is a tripeptide derived from alpha-MSH studied for anti-inflammatory effects in the gastrointestinal tract. Combined with BPC-157’s gut-protective profile, this stack is researched in models of inflammatory bowel disease and intestinal barrier integrity.

BPC-157 + GHK-Cu (skin and dermal research)

GHK-Cu is a copper-binding tripeptide studied for tissue remodeling and skin repair. The combination targets both deep tissue (BPC-157) and surface dermal (GHK-Cu) endpoints in wound research.

How it compares

Compared to TB-500: TB-500 acts primarily through actin-binding and cell migration mechanisms, while BPC-157 acts through VEGF, NOS, and growth-factor pathways. The two are complementary rather than competing, which is why they appear together in most tissue-repair stack research.

Compared to KPV: KPV is a smaller, anti-inflammatory tripeptide focused on gut and skin tissue. BPC-157 has broader tissue applicability but less focused anti-inflammatory specificity.

Compared to growth hormone secretagogues (e.g., CJC-1295, ipamorelin): GH secretagogues raise systemic IGF-1 levels and drive anabolic effects. BPC-157’s tissue-repair effects appear local and mechanistically distinct, which is why it is often researched alongside (rather than instead of) GH-axis compounds.

Frequently asked questions

What does BPC-157 stand for?

BPC-157 stands for Body Protective Compound, with 157 referring to the fifteen-amino-acid fragment of a larger gastric protective protein originally isolated from human gastric juice in the early 1990s.

Is BPC-157 stable enough for oral research administration?

Animal research has shown effects from oral administration, which is unusual for a peptide. The current understanding is that BPC-157 either survives gastrointestinal digestion intact or generates active metabolites that retain biological activity. The exact mechanism of oral bioavailability remains an active research question.

How does BPC-157 differ from TB-500 in research applications?

BPC-157 acts primarily through VEGF, nitric oxide synthase, and growth-factor pathways. TB-500 acts through actin-sequestering and cell migration mechanisms. The two are mechanistically complementary, which is why they are commonly studied together in tissue-repair research stacks.

What is the typical dose range used in published BPC-157 research?

Published animal studies use dose ranges from 10 microgram/kg to 10 mg/kg, with most studies clustering in the 10–500 microgram/kg range. Frequency varies from once daily to twice weekly depending on the endpoint studied.

How long does reconstituted BPC-157 last?

Reconstituted with bacteriostatic water and stored at 36–46°F (2–8°C), BPC-157 working solution is stable for approximately twenty-eight days. Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. (2018). Stable Gastric Pentadecapeptide BPC 157 in the Treatment of Colitis and Ischemia and Reperfusion in Rats. View source
2. Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. View source
3. Krivic A, Anic T, Seiwerth S, et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. View source
4. Seiwerth S, Brcic L, Vuletic LB, et al. (2014). BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. View source
5. Sikiric P, Seiwerth S, Brcic L, et al. (2010). Stable gastric pentadecapeptide BPC 157-NO-system relation. View source

Related research

Category

Best peptides for tissue repair research →

Compare

BPC-157 vs TB-500 →

Pair with

TB-500 research guide →

Pair with

GHK-Cu research guide →

Convenience

BPC-157 + TB-500 blend guide →